ERBB2 and neoplasm: Furthermore, animals treated with scFvNLDC-145-neu exhibited slower tumor growth compared with those treated with untargeted HER2 or neu DNA vaccine or control pcDNA3.1, resulting in prolonged survival of these mice, which indicated the induction of cross-reactivity toward HER2 antigen by scFvNLDC-145-neu vaccination.